Litcius/Paper detail

Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design

Alberto Bossi, Stéphanie Foulon, Xavier Maldonado, Paul Sargos, Paul Sargos, Paul Kelly, Aude Fléchon, Bertrand Tombal, S. Supiot, Dominik Berthold, Philippe Ronchin, Gabriel Kacsó, Naji Salem, Fabio Calabrò, Jean-François Berdah, Ali Hasbini, Marlon Silva, Jihane Boustani, Hélène Ribault, Karim Fizazi, Karim Fizazi, Alberto Bossi, Alberto Bossi, Stéphanie Foulon, Xavier Maldonado, Paul Sargos, Ray MacDermott, Paul Kelly, Aude Fléchon, Bertrand Tombal, Stephane Supiot, Dominik Berthold, Philippe Ronchin, Gabriel Kacso, Naji Salem, Fabio Calabro, Jean-François Berdah, Ali Hasbini, Marlon Silva, Jihane Boustani, Hélène Ribault, Karim Fizazi

2024The Lancet84 citationsDOI

Topics & Concepts

Prostate cancerMedicineOncologyRadiation therapyCastrationInternal medicineProstateOpen labelUrologyRandomized controlled trialGynecologyCancerHormoneProstate Cancer Treatment and ResearchProstate Cancer Diagnosis and TreatmentRadiopharmaceutical Chemistry and Applications
Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design | Litcius